RE: 🔥🚀massive RNS🚀🚀11 May 2026 08:17
CelLBxHealth has released a first quarter trading update for the three months to end March 2026. The period reflects the ongoing operational transformation within the business, most notably additional actions to right‑size the cost base, including further headcount reductions, with these activities expected to reduce annual cash operating costs by £6.6m during 2026. Cash at end‑1Q was £4.3m, in-line with expectations. While notable progress has been made in the internal transformation as the business pivots towards its revised CRO and clinical lab targeting strategy, CelLBxHealth has provided updated FY26 revenue guidance, noting that based on contracted revenues and near‑term pipeline conversion, the company now expects to deliver revenues of £2.1m in FY26 (vs FY26E Cavendish: £3.6m). We have revised our FY26E to align with this guidance but maintain our FY27-28E, reflecting management’s view on the robustness of the underlying sales pipeline.